The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone. As the world grapples with the outbreak, several healthcare companies are working to develop a vaccine against COVID-19. Let’s take a look at some of them:
Sanofi and Translate Bio
The latest to announce their work on a vaccine against the coronavirus are Sanofi Pasteur and Translate Bio (NASDAQ: TBIO). The companies today announced a partnership to develop a novel mRNA vaccine for COVID-19. The duo will work together to assess multiple SARS-CoV-2 vaccine candidates to push for advanced clinical development.
Sanofi Pasteur is the vaccines business division of Sanofi ADR (NASDAQ: SNY). This is Sanofi’s second collaboration in the development of a COVID-19 vaccine. The company already has an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop a protein-based vaccine candidate against the coronavirus.
Altimmune (NASDAQ: ALT), which announced its FY19 earnings results today, disclosed that it has begun the development of AdCOVID, an intranasal vaccine candidate against COVID-19. The company is working towards a Phase 1 clinical trial as early as the third quarter of this year.
Last week, Regeneron Pharmaceuticals (NASDAQ: REGN) said it has identified virus-neutralizing antibodies, which can be used in a cocktail therapy to prevent or treat the SARS-CoV-2 virus. In addition to this, Regeneron, along with Sanofi, announced the start of a Phase 2/3 clinical trial in order to evaluate Kevzara for the treatment of patients with severe COVID-19.
In February, Gilead Sciences (NASDAQ: GILD) announced the start of two Phase 3 clinical studies to assess the efficiency of remdesivir in the treatment of the novel coronavirus.
Last month, Moderna Inc. (NASDAQ: MRNA) said it released the first batch of its coronavirus vaccine, mRNA-1273, for human use. Vials of mRNA-1273 were shipped to the National Institute of Allergy and Infectious Diseases to be used in the Phase 1 study in the US.
Last week, the company announced that the first participant has been dosed in the Phase 1 study of the mRNA vaccine against COVID-19. The study will have two doses of vaccinations and the participants will be followed through 12 months after the second vaccination.
The IPO market witnessed a boom in 2020, despite the pandemic weakening the macro environment. Many tech companies have witnessed a blockbuster listing this year and few more tech firms
Micron Technology Inc. (NASDAQ: MU) reported strong earnings and revenue growth for the fourth quarter of 2020, benefitting from the pandemic-driven digital transformation spree. However, the company's stock dropped during
Mobile game company Zynga Inc. (NASDAQ: ZNGA) has seen its stock gain 49% since the beginning of this year. The company registered strong results in the first half of 2020